Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer
2018
Background
Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC.
Keywords:
- Small intestine adenocarcinoma
- Nab-paclitaxel
- Refractory
- Phases of clinical research
- Small bowel adenocarcinoma
- Colorectal cancer
- Oncology
- CpG Island Methylator Phenotype
- Medicine
- Internal medicine
- Febrile neutropenia
- Adenomatous polyposis coli
- Adenocarcinoma
- Response Evaluation Criteria in Solid Tumors
- Population
- Taxane
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
17
Citations
NaN
KQI